REPL Company Profile and Key Details

Q: Who are the executives of REPL?

Ms. Tanya N. Lewis M.S.Chief Devel. Operations OfficerDr. Pamela Esposito Ph.D.Chief Bus. OfficerMr. Sushil Patel Ph.D.Chief Commercial OfficerDr. Kostas Xynos M.B.A., M.D., Ph.D.Chief Medical OfficerAndrew SchwendenmanChief Accounting OfficerMr. Christopher SarchiChief Commercial OfficerMr. Philip Astley-Sparke FSAChief Executive Officer & DirectorDr. Sushil Patel Ph.D.Chief Strategy OfficerDr. Robert Coffin Ph.D.Founder, Pres, Chief R&D Officer and DirectorMr. Andrew SchwendenmanChief Accounting Officer & TreasurerDr. Konstantinos Xynos M.B.A., M.D., Ph.D.Chief Medical OfficerDr. Colin A. Love Ph.D.Chief Operating OfficerMr. Philip Astley-Sparke F.S.A., FSAChief Executive Officer, Interim Chief Financial Officer & DirectorMs. Jean M. FranchiChief Financial Officer, Treasurer, Sec. & Compliance Officer

NASDAQ : REPL

Replimune Group

$7.17

0.01+0.14%

At Close 4:00 PM

61.53

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Replimune Group, Inc. (REPL) stock surged +0.14%, trading at $7.17 on NASDAQ, up from the previous close of $7.16. The stock opened at $7.00, fluctuating between $6.79 and $7.36 in the recent session.

Stock Snapshot

7.16

Prev. Close

592.05M

Market Cap

6.79

Day Low

-2.08

P/E Ratio

-3.44

EPS (TTM)

-2.64

Cash Flow per Share

Open

82.57M

Number of Shares

7.36

Day High

82.02%

Free Float in %

6.33

Book Value

872.78K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 03, 2026	7.10	7.36	6.79	7.17	1.25M
Mar 02, 2026	7.43	7.57	7.02	7.16	1.43M
Feb 27, 2026	7.62	7.77	7.53	7.65	1.04M
Feb 26, 2026	8.16	8.35	7.68	7.69	1.03M
Feb 25, 2026	8.36	8.53	8.11	8.20	554.65K
Feb 24, 2026	8.49	8.61	8.25	8.36	874.73K
Feb 23, 2026	8.63	8.82	8.20	8.39	1.31M
Feb 20, 2026	8.47	8.72	8.32	8.64	1.56M
Feb 19, 2026	8.06	8.64	7.78	8.55	2.09M
Feb 18, 2026	7.23	8.35	7.22	8.04	3M
Feb 17, 2026	8.00	8.01	7.24	7.26	770.71K
Feb 13, 2026	7.96	8.41	7.87	7.97	909.55K
Feb 12, 2026	7.83	8.07	7.55	7.98	829.79K
Feb 11, 2026	7.79	7.89	7.43	7.76	721.46K
Feb 10, 2026	7.57	7.93	7.57	7.80	894.59K
Feb 09, 2026	7.64	7.89	7.53	7.78	771.16K
Feb 06, 2026	7.14	7.80	7.12	7.75	1.7M
Feb 05, 2026	7.03	7.38	6.79	6.93	1.67M
Feb 04, 2026	7.46	7.48	6.78	7.00	1.9M
Feb 03, 2026	7.03	7.46	6.94	7.38	1.09M

Contact Details

Woburn, MA 01801

United States

https://www.replimune.com 781 222 9600

About Company

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Stock Peers

REGN

-24.1-3.05%

Regeneron Pharmaceuticals, Inc.$766.66 ARGX

-8.04-1.06%

argenx SE$748.72 UTHR

-15.17-2.95%

United Therapeutics Corporation$498.65 VRTX

-11.76-2.42%

Vertex Pharmaceuticals Incorporated$474.27 MDGL

-9.77-2.24%

Madrigal Pharmaceuticals, Inc.$425.85 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-6.42-1.97%

Alnylam Pharmaceuticals, Inc.$318.65 PRAX

-12.37-3.74%

Praxis Precision Medicines, Inc.$318.22 KRYS

4.99+1.93%

Krystal Biotech, Inc.$263.80 ASND

-2.87-1.19%

Ascendis Pharma A/S$239.22

Frequently Asked Questions

What is the current Replimune Group, Inc. (REPL) stock price?

Replimune Group, Inc. (NASDAQ: REPL) stock price is $7.17 in the last trading session. During the trading session, REPL stock reached the peak price of $7.36 while $6.79 was the lowest point it dropped to. The percentage change in REPL stock occurred in the recent session was 0.14% while the dollar amount for the price change in REPL stock was $0.01.

REPL's industry and sector of operation?

The NASDAQ listed REPL is part of Biotechnology industry that operates in the broader Healthcare sector. Replimune Group, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of REPL?

Ms. Tanya N. Lewis M.S.
Chief Devel. Operations Officer
Dr. Pamela Esposito Ph.D.
Chief Bus. Officer
Mr. Sushil Patel Ph.D.
Chief Commercial Officer
Dr. Kostas Xynos M.B.A., M.D., Ph.D.
Chief Medical Officer
Andrew Schwendenman
Chief Accounting Officer
Mr. Christopher Sarchi
Chief Commercial Officer
Mr. Philip Astley-Sparke FSA
Chief Executive Officer & Director
Dr. Sushil Patel Ph.D.
Chief Strategy Officer
Dr. Robert Coffin Ph.D.
Founder, Pres, Chief R&D Officer and Director
Mr. Andrew Schwendenman
Chief Accounting Officer & Treasurer
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.
Chief Medical Officer
Dr. Colin A. Love Ph.D.
Chief Operating Officer
Mr. Philip Astley-Sparke F.S.A., FSA
Chief Executive Officer, Interim Chief Financial Officer & Director
Ms. Jean M. Franchi
Chief Financial Officer, Treasurer, Sec. & Compliance Officer

How REPL did perform over past 52-week?

REPL's closing price is 167.54% higher than its 52-week low of $2.68 where as its distance from 52-week high of $13.24 is -45.85%.

How many employees does REPL have?

Number of REPL employees currently stands at 479.

Link for REPL official website?

Official Website of REPL is: https://www.replimune.com

How do I contact REPL?

REPL could be contacted at phone 781 222 9600 and can also be accessed through its website. REPL operates from 500 Unicorn Park Drive, Woburn, MA 01801, United States.

How many shares of REPL are traded daily?

REPL stock volume for the day was 872.78K shares. The average number of REPL shares traded daily for last 3 months was 1.35M.

What is the market cap of REPL currently?

The market value of REPL currently stands at $592.05M with its latest stock price at $7.17 and 82.57M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	479
Beta	0.75
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	March
Sector	Healthcare
Industry	Biotechnology

Employees	479
Beta	0.75
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	March
Sector	Healthcare
Industry	Biotechnology

REPL Company Profile and Key Details

Replimune Group

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways